Ingerø Reiten Investment Company AS (“IRIC”) has today acquired 2.916.667 shares in Navamedic ASA, representing an ownership of 26.84% in the company. IRIC and related parties did not own any shares in Navamedic ASA prior to this transaction, and following the transaction holds 2.916.667 shares in total.
Paris, November 29, 2018 – happytal, French startup specializing in enhancing inpatient experience, announces it
has closed a €20 million equity fundraising led by AXA Venture Partners (AVP) and backed by existing shareholders
Partech and Compagnie d’Anjou and new shareholder Alliance Entreprendre, together with a €3 million loan from
Bpifrance.
Funds raised will allow happytal to step up its roll-out in hospitals, medical centres and retirement homes in France
and abroad. As Pass French Tech prize-winner last July, happytal will also draw on funds raised to enhance its hightech platform, which is blazing a trail in making online patient procedures user-friendly and easy.
To support its growth, 200 new top-class staff will be hired in 2019, primarily for business development, tech and
operations.
happytal was founded in 2013 by health industry-savvy founders and strives to revolutionize patients’ quality of life
throughout their healthcare journey from pre-admission until they return home. Patients and their loved ones can
carry out pre-admission procedures online, request a private room, instantly give a satisfaction rating and enjoy a
broad concierge services offering to smooth and improve their inpatient stay, including wellbeing, delicacies,
flowers, health products and home help. To provide such services, happytal engages personally selected artisans
and carers from nearby the health establishment, thereby contributing to local economies.
Five years since it was founded, happytal is now present in over 70 healthcare establishments in France and
Belgium, and has so far created over 300 jobs in the regions and at its Paris head office. Over 25,000 patients, their
loved ones and hospital staff have been won over by happytal and use it every month with a 95+ per cent
satisfaction score!
Pierre Lassarat, happytal co-founder and CEO, said: “Our rapid growth testifies that our people-focused and techbased services are very popular with healthcare establishments, which increasingly need user-friendly and nimble
systems. Our vibrant and dynamic people and the trust our users have in us mean we can expand our offering, take
on more staff and continue to invest”.
Romain Revellat, happytal joint founder and chairman, exclaimed: “We are thrilled to welcome new investors – AXA
Venture Partners (AVP) & Alliance Entreprendre – while pursuing our new business venture with our existing
shareholders – Partech and Compagnie d’Anjou. Their trust in us and this additional big equity investment are
testimony to our success while also reflecting our determination to maintain growth and make happytal a partner
of choice for patients and their loved ones”.
About happytal
The startup Happytal seeks to revolutionize hospital inpatient experience end-to-end by helping patients through all procedures right from
pre-admission to returning home, while providing concierge services, which smooth their stay and make it easier for their loved ones to help
them remotely. happytal’s solution also extends to a broad range of hospital services designed to enhance hospitals’ appeal and put patient procedures online – online pre-admission, online private room request, discharge lounges, real-time satisfaction measures etc.
happytal was set up in 2013 by healthcare industry-savvy founders and is now present in over 70 healthcare establishments in France and Belgium and every month attracts 25,000-plus patients, loved ones and hospital staff users. To learn more go to www.happytal.com
happytal is a Silver Alliance member. Silver Alliance, comprising 18 companies engaged in old people care, was formed in 2018 to bring about teamwork among entrepreneurs in ways that will benefit society at large, stimulate the economy and create local jobs. To learn more go to www.silveralliance.fr
About AXA Ventures Partners
AXA Venture Partners (AVP) is a venture capital fund investing in high-growth, technology-enabled companies. AVP manages $450m broken down between $275m direct investments and $175m for its Fund of Funds business. To date, AVP has invested in some forty seed and growth equity deals. AVP teams operate globally backed by offices in San Francisco, New York, London, Paris and Hong Kong.
To learn more go to www.axavp.com. Contact: François Robinet (francois@axavp.com) / Sébastien Loubry (sebastien@axavp.com)
About Partech
Partech is a big private equity investor in grand-breaking businesses from its offices in San Francisco, Paris, Berlin and Dakar. The firm’s people provide funds, operational experience and strategic advice to entrepreneurs at all stages of development including seed, venture and growth investments. The firm’s investment capacity exceeds €1 billion. Equity investments range from €200,000 to €50m and cover a broad range of technologies, goods and corporate and consumer services including IT systems, online brands, services, hardware and deep tech. To date,
Partech-backed companies have completed 20-plus IPOs and the firm has sold over 50 $100m-plus strategic investments. Partech’s current portfolio: https://partechpartners.com/companies/
Press Contact
Agence Ballou PR
Mickaël Barreteau & Isabelle Renard
Nordstjernan’s subsidiary Lideta, which also includes the Mama Mia health care group, has signed an agreement to acquire the Primary Health Care business area from Aleris. The acquisition covers a total of eleven health care centers in the Stockholm region and Uppsala, with 107,000 listed patients. The company has 275 full-time employees, and sales for 2018 were estimated at SEK 325 million. The acquisition is conditional upon approval from the relevant competition authorities. After the acquisition, Lideta will have 247,000 listed patients and approximately 775 employees, and it is estimated that sales will increase around 40 percent to just over SEK 1 billion. Lideta will thus become Sweden’s third largest private operator in primary health care.
In 2017, Nordstjernan acquired the health care companies Lideta and Mama Mia with the intent of developing a high-quality operator in Swedish health and medical care, with a focus on primary health care. The acquisition of Aleris’s Primary Health Care business area is part of its focus on primary health care.
“Nordstjernan believes that private health and medical care will play a central role in meeting patients’ growing needs for accessibility and quality. We believe that much of this future expansion will take place in the important field of primary health care. With Lideta’s acquisition of health care centers from Aleris, we will continue to expand in the welfare sector as a long-term owner,” said Nordstjernan’s President and CEO Tomas Billing.
Tomas Billing
President and CEO
Nordstjernan AB
Questions will be answered by:
Tomas Billing, CEO, Nordstjernan
Telephone: +46 8 788 50 18
E-mail: tomas.billing@nordstjernan.se
Stefan Stern, Senior Advisor, Nordstjernan
Telephone: +46 70 636 74 17
E-mail: stefan.stern@nordstjernan.se
CBPE Capital (“CBPE”) has invested to acquire a majority ownership position in Blatchford, a world leading provider of advanced prosthetic and orthotic (“P&O”) devices. CBPE will be investing alongside fourth generation family member Stephen Blatchford and the management team led by Adrian Stenson, CEO. Terms of the transaction have not been disclosed.
Blatchford provides highly innovative, premium quality prosthetic and orthotic devices to lower-limb patients across the world. Over 80% of product sales are outside of the UK. As well as designing, manufacturing and distributing products, Blatchford also operates clinical service centres in the UK and Norway, providing valuable patient feedback into the research and development process for new products.
The company will continue its dedication to and focus on developing innovative products that lead to improved clinical outcomes and enhanced quality of life for patients. The ongoing investment in R&D, under the stewardship of Professor Sir Saeed Zaheedi, has resulted in pioneering prosthetics such as Linx, the world’s first and only truly integrated microprocessor-controlled limb system. This patient-centric culture extends into the clinical divisions of Blatchford where patients receive market-leading, quality rehabilitation services.
CBPE will support management’s plans to bring a range of innovative new products to market and to expand the business geographically, both organically and through acquisitions.
The investment in Blatchford continues CBPE’s successful track record of investing in and developing market-leading, high-growth healthcare businesses. The current portfolio includes Rodericks, a leading provider of dental services, SpaMedica, a leading provider of ophthalmic services, OH Assist, the largest occupational health services provider in the UK, Medica Reporting which is the UK market leader in teleradiology, and Assisted Reproduction & Gynaecology Centre (ARGC) the leading fertility clinic in the UK.
Naveen Passi, Director, CBPE said: “Blatchford provides life-changing products and is a technology-leader in the P&O field. Stephen and Adrian have led the business through a period of substantial growth and we are delighted to be supporting the business in the next phase of its development.”
Adrian Stenson, CEO of Blatchford said: “In CBPE we have found an investor that shares our values, has taken the time to understand the direct effect we have on people’s lives and will help us build our brand and what we stand for on the global stage. CBPE has a track record of successful direct investment in the healthcare area and we look forward to working as a close team to continue delivering exceptional outcomes for patients and stakeholders alike.”
CBPE’s investment in Blatchford was led by Naveen Passi and Ian Moore with support from Rupert Parker and Aqil Sohail. Naveen Passi and Ian Moore will join the Board of Blatchford.
Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals today announced the completion of a series-A financing round, whereby the company secured funding of EUR 37 million. Gimv, who leads this round together with V-Bio Ventures, invests EUR 6 million. They are joined by HealthCap, Novo Seeds, Pontifax and BioMedPartners. This financing, which is one of the larger rounds of a European early-stage life sciences company, will enable Camel-IDS to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.
Camel-IDS (www.camel-ids.com), which was founded in 2014 as a spin-off from Vrije Universiteit Brussel (VUB), develops novel radiopharmaceuticals, using camelid domain antibodies linked to radionuclides. Breast cancer patients with tumors that overexpress HER2, a growth-promoting protein, can benefit from effective targeted treatments today. However, they have a poor prognosis when the cancer progresses towards the brain. Camel-IDS’ lead program shall be used to effectively irradiate such brain lesions while sparing healthy tissue. This is based on its unique technology platform that leverages the favourable tissue distribution of camelid derived single domain antibodies linked to radionuclides.
Karl Naegler, Partner in Gimv’s Health & Care platform, adds: ‘From early on in our discussions, the renowned expertise of the Camel-IDS’ team in radio-immunotherapy became clear, with Prof. Tony Lahoutte bringing exceptional knowledge to the table. Together with Ruth Devenyns as CEO, an industry veteran of the European biotech landscape and successful entrepreneur, the company is well positioned to move up to the next level.’
This investment marks Gimv’s 4th investment in the life sciences, medtech and healthcare sector this year, thus further underpinning Gimv’s position as one of the most active European investors in the healthcare industry. Moreover, this brings the total number of portfolio companies in the Health & Care investment platform to no less than 21.
For further information, we refer to the company’s press release in attachment.
Utrecht (The Netherlands), Cambridge (United States) – Respiratory device producer Vapotherm, Inc. announced its Initial Public Offering and listing on the NYSE exchange. Shares in the IPO are issued to institutional investors in the US and Europe, raising gross proceeds of $56 million. The offering was significantly oversubscribed. The total market capitalisation of Vapotherm will be $244 million at the introduction price and shares will trade under the ticker symbol VAPO.
The new funds enable Vapotherm to continue ramping sales of its Hi-VNI® technology in the US and Europe. Vapotherm’s Hi-VNI® treats patients in respiratory distress in the neo-natal intensive care unit (ICU), the adult ICU, the emergency department, post-acute care and for patients in hospice. The technology has been proven equivalent to the gold standard of non-invasive ventilation, however can be delivered without the need for a mask, providing patients with more comfort and flexibility in their care.
In addition to ramping sales with existing products, Vapotherm will use proceeds from the IPO to pursue an aggressive product development program which includes products which automate the delivery of oxygen based on feedback from a patient’s oxygen levels; and a portable device which has the potential to be used in expanded clinical settings, including the home.
Gilde Healthcare acted as lead investor in the Series B financing for Vapotherm and will remain represented on the board of Vapotherm post listing. During Gilde’s investment period Vapotherm tripled US and International revenues, established a highly specialized direct sales force, and dramatically increased gross margins.
Bank of America Merrill Lynch and William Blair acted as Joint Bookrunners in connection with the IPO. Canaccord Genuity acted as lead manager and BTIG acted as co-manager.
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com
Nordic Healthcare Group (NHG), a Finnish healthcare and social services advisory and analytics company, is expanding its value-based services in the Nordic Countries. NHG employs more than 100 professionals that help its clients develop influential services for future needs. NHG is the leading player in its field in Finland and aims to be the market leader in the Nordic Countries.
”NHG helps its clients build value-based health and social service operations by integrating cost, quality and customer experience data and analytics in their operations and management systems. We want to build better social services and healthcare in the Nordic Countries, with the vision of building a value-based service system. We combine analytics with expertise and experience in solving critical challenges and implementing the best practices”, says Vesa Kämäräinen, President & CEO of Nordic Healthcare Group.
Value-based delivery is a global megatrend in the social and healthcare sector and it is enabled by technological advances. Cost pressures, demographic changes and the consumerisation of healthcare have given rise to the need for measuring value in social and healthcare services, both in the Nordic Countries and globally. Value is measured by health outcomes relative to the cost of delivery.
To implement the company’s growth strategy, NHG and private equity firm Vaaka Partners have completed a transaction in which Vaaka Partners invests in Nordic Healthcare Group. Vaaka Partners is an active and growth-oriented partner that has been involved in the successful growth and internationalisation of a number of Finnish companies, such as Framery, Solita and Musti ja Mirri.
Vaaka Partners’ investment will accelerate the implementation of NHG’s Nordic growth strategy and enable acquisitions, investments in R&D and the development of competencies. The aim is to build on NHG’s existing strengths to create a Nordic company focused on the advancement of value-based healthcare and social services in the Nordic Countries. NHG’s ambition is to be the leading social and healthcare advisory and analytics company in the Nordics.
“We have contributed to NHG’s growth strategy and will be able to support the company in its implementation. NHG has superior expertise in its field, within the domains of analytics, service, leadership and management development, as well as transformation, which has great international potential. We are looking forward to supporting NHG’s key personnel in the implementation of the business plan together with an experienced Board”, says Antti Salmela of Vaaka Partners.
The parties have agreed that the terms of the transaction will not be disclosed. After the transaction, Nordic Healthcare Group will be owned by Vaaka Partners, the key personnel and founders of NHG and the members and advisors of the Board of Directors. In addition to the representatives of Vaaka, NHG’s Board of Directors will consist of Juko Hakala (Chairman), Marianne Saarikko Janson, Hannu Vaajoensuu and Petri Parvinen.
Additional information:
Nordic Healthcare Group
Vesa Kämäräinen, President & CEO
vesa.kamarainen@nhg.fi
+358 50 545 9025
Vaaka Partners Ltd
Antti Salmela, Partner
antti.salmela@vaakapartners.fi
+358 50 540 4640
Nordic Healthcare Group
Nordic Healthcare Group is a Finnish growth company founded in 2004. Our clients include hospital districts, municipalities, private service providers, pharmaceutical companies, private equity investors and healthcare technology companies. We employ more than 100 experienced professionals and young talents. Read more at www.nhg.fi
Ghent, Belgium: 8 November 2018 – Sequana Medical nv, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the appointments of Pierre Chauvineau as Chairman and Wim Ottevaere as non-executive director of the Company effective as of the closing of the intended Initial Public Offering announced today. Pierre will succeed Rudy Dekeyser as Chairman, who will remain a non-executive director.
More info on Sequana’s website.
Stockholm, November 7, 2018
CCS Healthcare has entered into agreements to divest its Consumer Skincare business unit. CCS’s factory and contract manufacturing activities in Borlänge, Sweden, will be sold to Svenska Krämfabriken AB and the Group’s portfolio of skincare brands sold in Sweden, Norway, Finland and the UK will be acquired by Trimb Healthcare AB.
Following the divestments, CCS will be exclusively focused on hygiene and safety products in the professional business-to-business markets.
The transactions are expected to be completed in January 2019.
CCS Healthcare is a portfolio company of Segulah IV L.P.
For further information, please visit www.ccshc.com, www.segulah.com or contact:
Johan Möllerström, Investment Manager, Segulah Advisor AB, +46 72 543 79 11
Helsinki, Finland: 25 October 2018 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing, and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), announces today that it has secured € 342 thousand in the form of future R&D loans from Business Finland. The funding is part of the ELASTRONICS project to develop wireless Electromyography (EMG) devices. ELASTRONICS (Enabling the Future of Wearable Electronics) is Finland’s largest research project for stretchable electronics technologies and production processes.
